KR102132604B1 - 비형 간염 표면 항원에 대한 항체 및 그의 용도 - Google Patents

비형 간염 표면 항원에 대한 항체 및 그의 용도 Download PDF

Info

Publication number
KR102132604B1
KR102132604B1 KR1020187013043A KR20187013043A KR102132604B1 KR 102132604 B1 KR102132604 B1 KR 102132604B1 KR 1020187013043 A KR1020187013043 A KR 1020187013043A KR 20187013043 A KR20187013043 A KR 20187013043A KR 102132604 B1 KR102132604 B1 KR 102132604B1
Authority
KR
South Korea
Prior art keywords
seq
antibody
antigen
delete delete
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187013043A
Other languages
English (en)
Korean (ko)
Other versions
KR20180084045A (ko
Inventor
웬신 루오
빙 주
주안 장
콴 유안
티안잉 장
준 장
닝샤오 시아
Original Assignee
시아먼 유니버시티
양셍탕 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시아먼 유니버시티, 양셍탕 컴퍼니 리미티드 filed Critical 시아먼 유니버시티
Publication of KR20180084045A publication Critical patent/KR20180084045A/ko
Application granted granted Critical
Publication of KR102132604B1 publication Critical patent/KR102132604B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020187013043A 2015-10-09 2016-10-09 비형 간염 표면 항원에 대한 항체 및 그의 용도 Active KR102132604B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510647977.7 2015-10-09
CN201510647977 2015-10-09
PCT/CN2016/101560 WO2017059813A1 (zh) 2015-10-09 2016-10-09 抗乙肝表面抗原的抗体及其用途

Publications (2)

Publication Number Publication Date
KR20180084045A KR20180084045A (ko) 2018-07-24
KR102132604B1 true KR102132604B1 (ko) 2020-07-13

Family

ID=58487306

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187013043A Active KR102132604B1 (ko) 2015-10-09 2016-10-09 비형 간염 표면 항원에 대한 항체 및 그의 용도

Country Status (10)

Country Link
US (1) US10689434B2 (enExample)
EP (1) EP3360896B1 (enExample)
JP (2) JP6949012B2 (enExample)
KR (1) KR102132604B1 (enExample)
CN (1) CN106565840B (enExample)
AU (1) AU2016334290B2 (enExample)
BR (1) BR112018007121A2 (enExample)
CA (1) CA3001231C (enExample)
ES (1) ES3041684T3 (enExample)
WO (1) WO2017059813A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016334290B2 (en) * 2015-10-09 2020-06-18 Xiamen University Antibody to hepatitis B surface antigen and use thereof
MY208015A (en) * 2018-05-31 2025-04-07 Univ Tokyo Anti-human tlr7 antibody
CN112165974B (zh) * 2018-05-31 2024-11-08 诺华股份有限公司 乙型肝炎抗体
JP7454855B2 (ja) * 2018-12-21 2024-03-25 国立大学法人広島大学 抗ｐｒｅＳ１抗体およびその用途
JP7607289B2 (ja) * 2019-05-23 2024-12-27 シァメン・ユニヴァーシティ 新規の抗ｂ型肝炎ウイルス抗体及びその使用
CN111242107B (zh) * 2020-04-26 2021-03-09 北京外号信息技术有限公司 用于设置空间中的虚拟对象的方法和电子设备
WO2024148263A1 (en) * 2023-01-06 2024-07-11 Victorian Infectious Diseases Reference Laboratory Methods and compositions for antibody treatment of hepatitis b infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517636A (ja) 2000-10-02 2004-06-17 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー Ｂ型肝炎ウイルスの表面抗原ｓに対するヒト化抗体及びその製造方法
WO2009093263A1 (en) 2008-01-23 2009-07-30 Department Of Biotechnology A humanized high affinity recombinant antibody against hepatitis b surface antigen
JP2013515477A (ja) 2009-12-24 2013-05-09 グリーン クロス コーポレーション Ｂ型肝炎ウイルス表面抗原に特異的に結合するヒト抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1560081A (zh) * 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
CN102786592A (zh) * 2011-05-17 2012-11-21 傅阳心 Hbv特异性抗体
US9751914B2 (en) 2012-06-11 2017-09-05 Xiamen University Polypeptides and antibodies for treating HBV infection and related diseases
AU2013287516B2 (en) * 2012-07-10 2016-07-07 Green Cross Corporation An antibody composition for prevention or treatment of mutant hepatitis B virus infection
WO2015107126A1 (en) * 2014-01-16 2015-07-23 Mondelli Mario Umberto Francesco Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
AU2016334290B2 (en) * 2015-10-09 2020-06-18 Xiamen University Antibody to hepatitis B surface antigen and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517636A (ja) 2000-10-02 2004-06-17 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー Ｂ型肝炎ウイルスの表面抗原ｓに対するヒト化抗体及びその製造方法
WO2009093263A1 (en) 2008-01-23 2009-07-30 Department Of Biotechnology A humanized high affinity recombinant antibody against hepatitis b surface antigen
JP2013515477A (ja) 2009-12-24 2013-05-09 グリーン クロス コーポレーション Ｂ型肝炎ウイルス表面抗原に特異的に結合するヒト抗体

Also Published As

Publication number Publication date
EP3360896B1 (en) 2025-07-23
AU2016334290A1 (en) 2018-05-10
KR20180084045A (ko) 2018-07-24
US20190389939A1 (en) 2019-12-26
AU2016334290B2 (en) 2020-06-18
CA3001231C (en) 2022-07-12
CA3001231A1 (en) 2017-04-13
US10689434B2 (en) 2020-06-23
CN106565840B (zh) 2020-09-01
CN106565840A (zh) 2017-04-19
JP2018533937A (ja) 2018-11-22
JP2021063092A (ja) 2021-04-22
EP3360896A4 (en) 2019-08-28
WO2017059813A1 (zh) 2017-04-13
JP6949012B2 (ja) 2021-10-13
EP3360896A1 (en) 2018-08-15
ES3041684T3 (en) 2025-11-13
BR112018007121A2 (pt) 2018-11-06

Similar Documents

Publication Publication Date Title
KR102132604B1 (ko) 비형 간염 표면 항원에 대한 항체 및 그의 용도
JP5818804B2 (ja) ヒトｉｌ−２２ｒａに対するヒト化抗体
HK1247214B (zh) 一种pdl-1抗体、其药物组合物及其用途
KR102561555B1 (ko) Ｂ형 간염 감염 및 관련 질병의 치료를 위한 항체
KR20220167331A (ko) 항-flt3 항체 및 조성물
JP2023543826A (ja) 抗ｃｄ３抗体およびその使用
KR20170110681A (ko) Pcsk9 항체, 및 약제학적 조성물 및 이의 용도
KR20210121102A (ko) 항-cd79b 항체, 이의 항원-결합 단편, 및 이의 약학적 용도
JP2022507599A (ja) 安定性が向上した抗ｃ－ｍｅｔ抗体又はその抗原結合断片
AU2021289612A1 (en) HIV-1 antibodies
CN108178798B (zh) pH工程化的NGF抗体及其医药用途
CN112996540B (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
KR102769097B1 (ko) 항-b형 간염 바이러스 항체 및 이의 용도
CN115197323A (zh) 一种sn38抗体或其抗原结合片段及其应用
CN113549146A (zh) 针对柯萨奇病毒b1型的单克隆抗体及其用途
RU2841957C1 (ru) Сконструированные антитела против il-2
WO2024123897A1 (en) Broadly neutralizing and potent antibodies against hiv
TW202500581A (zh) 用於治療慢性D型肝炎之抗HBsAg抗體
CN121005780A (zh) 靶向hla-g的抗体或其抗原结合片段及其应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180508

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181010

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191217

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200627

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200706

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200707

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230615

Start annual number: 4

End annual number: 4